Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57d46efd85795ce5969a79f03a6a2c1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a77b8cc427db284b23b54636b37e89a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd2c3900689abdaedb13713965cfb0fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b53290ef881bc16e92cfbaf0cd9605a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e1b9cb5512d4a530c7b0e523dbcee30 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2002-91541 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-915 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-02 |
filingDate |
2006-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_301c2fc918c63d3084b3b10ee3f2ce86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_517d82f0a3a3cad860b42988c5a203d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22bade2a7b32e7d68b521552bb06d6af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_481013b3de846d5d8da262c2252ec1e4 |
publicationDate |
2006-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2006099381-A1 |
titleOfInvention |
Drug delivery stent with extended in vivo and in vitro release of anti-inflammatory |
abstract |
A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti- restenotic agent , such as Pimecrolimus, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 45 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008264527-A |
priorityDate |
2005-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |